LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Posts Its Biggest Quarter Ever as Weight-Loss Drugs Surge — But Can Pricing Pressure Keep Up With the Hype?
Shares surged more than 10% as Eli Lilly delivered what CEO Dave Ricks called an unprecedented streak: "Impressively, it's like our fifth or sixth quarter in...
🟢 LLY is trading 10.41% up today after a massive Q1 earnings beat and raised full-year guidance
LLY is trading at $939.84 (+10.41%) following a blockbuster Q1 2026 earnings report and an upward revision to its full-year financial outlook. • The company...
Eli Lilly Shares Soar 9% on Massive Q1 Beat and Raised Outlook
Eli Lilly reported Q1 CY2026 revenue of $19.8 billion. This figure represents 55.5% year-over-year growth. The revenue total beat analyst estimates by...
Eli Lilly and Company Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
For the first quarter of 2026, analysts anticipate Eli Lilly and Company to report consensus revenue of approximately $17.78 billion and adjusted earnings of...
Eli Lilly signs $2.25 billion Profluent deal, targeting AI gene editing
Eli Lilly partnered with Profluent on April 28, 2026, to develop AI-driven genetic medicines. The collaboration carries a potential total value of $2.25...
Eli Lilly acquires Ajax Therapeutics for $2.3B, targeting rare blood cancers
Eli Lilly signed a deal to acquire Ajax Therapeutics for up to $2.3 billion. The transaction includes an upfront cash payment and future milestone-based...
Eli Lilly Shares Fall, Zepbound Prescriptions Lag Behind Rival Wegovy
Eli Lilly shares fell 2% in premarket trading on Friday. The decline followed the release of weekly prescription data for the period ending April 17. Total...
🔴 LLY is trading 3.22% down
LLY is trading at $888.07, down 3.22%.
🔴 LLY is trading 3.6% down on Amazon's entry into GLP-1 drug market
LLY is trading at $884.99 (-3.6%) in pre-market action after Amazon announced the launch of a new GLP-1 obesity drug program, creating a significant new...
🔴 LLY is trading 3% down today amid sector volatility and geopolitical tensions
LLY is trading at $889.81 (-3.03%) in pre-market action on April 24, 2026, following a close of $917.65 the previous day. The decline occurs despite a lack of...
Eli Lilly Expands Telehealth Reach for Zepbound Through Hims & Hers Platform
Hims & Hers expanded its platform functionality. Healthcare providers can now prescribe Eli Lilly’s weight-loss drug Zepbound in vials and KwikPen formats to...
Eli Lilly Shares Slide, Driven by CVS Medicare Obesity Model Exit
Eli Lilly shares fell as much as 3.8% after CVS Health opted out of a Medicare model for obesity medications. [7, 8] The decision threatens market penetration...
Eli Lilly acquires Kelonia for $7 billion, diversifying beyond obesity drugs
Eli Lilly and Company entered a definitive agreement to acquire clinical-stage biotechnology firm Kelonia Therapeutics. The deal includes an upfront payment of...
Eli Lilly nears Kelonia acquisition, targeting next-gen cancer gene therapy
Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics, a privately-held biotechnology firm. A formal announcement could occur as early as...
Eli Lilly’s Foundayo pill debuts with 1,390 prescriptions, boosting shares 2%
Eli Lilly’s oral weight-loss drug Foundayo recorded 1,390 prescriptions for the week ending April 10. Analysts estimate this total reflects only two days of...
Eli Lilly Faces FDA Safety Probe, Citing Obesity Drug Liver Risks
The U.S. Food and Drug Administration (FDA) requested additional data from Eli Lilly regarding potential liver injury risks for its new obesity treatment. This...
Eli Lilly buys CrossBridge Bio for $300M, boosting next-gen cancer pipeline
Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million. The deal adds dual-payload antibody-drug conjugates to Lilly’s oncology...
Eli Lilly reports Jaypirca success, meeting Phase 3 leukemia trial goals
Eli Lilly and Company reported positive topline results from its Phase 3 BRUIN CLL-322 trial for Jaypirca (pirtobrutinib). The study evaluated Jaypirca in...
Eli Lilly launches Foundayo oral pill, disrupting obesity market with $149 pricing
Eli Lilly released its once-daily oral weight-loss pill, Foundayo (orforglipron), in the United States. The medication targets adults with obesity or those who...
Eli Lilly target raised to $1,294, following FDA approval of Fundayo
BofA analyst Jason Gerberry raised the Eli Lilly (LLY) price target to $1,294. The previous price target for the pharmaceutical firm was $1,293. This revision...